Targeting the PD-1/PD-L1 axis with immune checkpoint inhibitors has exhibited good potential in restoring antitumor immunity and specifies a potential therapeutic strategy for treating melanomas in humans and dogs (25, 26). The gene discussed is CD274; the disease is melanoma.